Medical Reviewer

Dr. SangYoul Yun

Korean Board-Certified Dermatologist

Dr. SangYoul Yun is a Korean board-certified dermatologist who medically reviews DermatologyNews articles.

Articles

Bar chart from a comparison of 878 retracted publications in 131 high-impact medical journals: the Retraction Watch Database identified 92.8 percent, PubMed 86.3 percent and Web of Science 83.6 percent, with coverage varying by discipline.

How to check if a dermatology study is retracted

Learn how to check a dermatology paper in PubMed for corrections, expressions of concern and retractions, and how to read each notice accurately.

Oct 19, 2026 · 7 min · Medically reviewed

Dot chart of adverse reactions in the first 16 weeks of the adult atopic dermatitis trials in the Dupixent US label, including injection-site reactions (10 versus 5 percent) and conjunctivitis (10 versus 2 percent) with dupilumab versus placebo.

Medical

Dupilumab (Dupixent) side effects: what the label and trials report

Injection-site reactions, conjunctivitis and facial redness: what the Dupixent label and phase 3 trials show, and which symptoms the label says to report.

Oct 19, 2026 · 9 min · Medically reviewed

Summary of the evidence in the manufacturer's 510(k) submission for K260618: three knee studies with 44 subjects in total, assessed on several clinical endpoints.

News

Ulthera's 2026 knee skin-laxity clearance: what changed

The FDA added knee skin laxity to Ulthera's US indications in May 2026. Read what changed, what the small studies show, and questions to ask a clinician.

Oct 19, 2026 · 4 min · Medically reviewed

Bar chart from a post hoc analysis in adolescents aged 12 to 17 with moderate-to-severe acne: at week 12, 51.5 percent of 123 using clindamycin, adapalene and benzoyl peroxide gel reached treatment success versus 24.9 percent of 50 using vehicle.

Medical

Teen acne: what the 2024 acne guideline recommends

Which acne treatments carry strong recommendations for adolescents in the 2024 American Academy of Dermatology guideline, what the trials behind them found, and where the evidence is thin.

Sep 12, 2026 · 8 min · Medically reviewed

Timeline of how bemotrizinol entered the US sunscreen monograph: request submitted September 23, 2024, proposed order December 12, 2025, final order June 10, 2026, effective August 9, 2026.

News

Bemotrizinol: what the first new US sunscreen filter in 20 years adds

The FDA added bemotrizinol to the OTC sunscreen monograph in June 2026. What the order allows, what absorption and stability data show, and what is unknown.

Sep 4, 2026 · 7 min · Medically reviewed

Bar chart from a 624-patient randomized trial: 12 months after field treatment, 74.7 percent stayed free of treatment failure with 5 percent fluorouracil cream, 53.9 percent with imiquimod, 37.7 percent with photodynamic therapy and 28.9 percent with ingenol mebutate.

Medical

Actinic keratosis: how field-directed treatments compare

Actinic keratosis is a precursor to squamous cell carcinoma. What the progression data show, and how fluorouracil, imiquimod, and photodynamic therapy compared in a head-to-head trial.

Aug 27, 2026 · 8 min · Medically reviewed

Stacked bars for the same patients a median of 4.3 months after one microfocused ultrasound session: blinded investigators rated 20.9 percent improved, while the patients rated 45.9 percent improved.

Aesthetic

Energy-based lifting: how many sessions do the data support?

Standard microfocused ultrasound protocols are single-session. What the evidence says about repeating treatment, combining devices in one visit, and why patient and investigator ratings diverge.

Aug 27, 2026 · 7 min · Medically reviewed

$Grid of three randomized keratosis pilaris trials: roughness improved versus control with Nd:YAG laser, intense pulsed light and fractional CO2 laser, while redness did not respond in the same way.$

Patient Ed

Keratosis pilaris: what the evidence actually supports

The rough bumps on upper arms and thighs are common and harmless. What trials show about keratolytics, lasers, and intense pulsed light, and why recurrence is the expected outcome.

Aug 27, 2026 · 6 min · Medically reviewed

Range chart of reported minimum inhibitory concentrations for Trichophyton indotineae: terbinafine values span 0.04 to 32 micrograms per millilitre or more, while most itraconazole values sit below 1.

News

Terbinafine-resistant tinea: what Trichophyton indotineae changes

An emerging dermatophyte species is poorly responsive to terbinafine and cannot be identified without molecular testing. What the resistance data show and what they change in practice.

Aug 27, 2026 · 6 min · Medically reviewed

Diagram of what happens to the skin barrier as autumn humidity and temperature fall: transepidermal water loss rises and reactivity increases, with moisturizer classes that counter each change.

Patient Ed

Autumn skin barrier repair: what the evidence supports

Falling humidity and temperature measurably weaken the skin barrier. What changes in autumn, what moisturizers do, and when dryness needs a doctor.

Aug 13, 2026 · 5 min · Medically reviewed

Timeline diagram of seasonal hair shedding: the proportion of resting telogen hairs peaks in summer, and shedding is inferred to rise two to three months later in early autumn before follicles re-enter growth.

Patient Ed

Seasonal hair shedding: why it peaks in autumn

Hair shedding follows an annual rhythm that peaks in early autumn. What trichogram and search data show, how much is normal, and when to seek care.

Aug 13, 2026 · 6 min · Medically reviewed

Evidence snapshot for seborrheic dermatitis: winter-dominant prevalence in the Rotterdam Study and IGA success rates for roflumilast foam versus vehicle in phase 2a and phase 3 trials.

Medical

Seborrheic dermatitis: autumn flares and new treatments

Why seborrheic dermatitis flares as weather cools, plus trial evidence on roflumilast foam, the first FDA-approved PDE4 inhibitor for the disease.

Aug 13, 2026 · 7 min · Medically reviewed

MedicalDermatologyNews

Medical

Oral JAK inhibitors for alopecia areata: FDA labels compared

Baricitinib, ritlecitinib, and deuruxolitinib are FDA approved for severe alopecia areata. Compare age limits, trials, boxed warnings, and evidence gaps.

Aug 1, 2026 · 6 min · Medically reviewed

MedicalDermatologyNews

Medical

Clascoterone for acne: topical antiandrogen evidence

Clascoterone is an FDA-approved topical androgen receptor inhibitor for acne. See the phase 3 results, limits, adverse effects, and unanswered comparisons.

Aug 1, 2026 · 5 min · Medically reviewed

MedicalDermatologyNews

Medical

Delgocitinib for chronic hand eczema: trial evidence

Delgocitinib cream is FDA approved for some adults with chronic hand eczema. Review the phase 3 results, label limits, safety warnings, and evidence gaps.

Aug 1, 2026 · 5 min · Medically reviewed

NewsDermatologyNews

News

FDA RF microneedling safety communication: key facts

The FDA received reports of serious complications with certain RF microneedling uses in 2025. Learn what was reported, remains unknown, and how needling differs.

Aug 1, 2026 · 6 min · Medically reviewed

MedicalDermatologyNews

Medical

Lebrikizumab and nemolizumab: atopic dermatitis evidence

Lebrikizumab and nemolizumab target different atopic dermatitis pathways. Compare their FDA labels, phase 3 designs, safety limits, and evidence gaps.

Aug 1, 2026 · 5 min · Medically reviewed

MedicalDermatologyNews

Medical

Ruxolitinib cream for vitiligo: evidence and limits

Ruxolitinib cream can improve facial repigmentation in some people with nonsegmental vitiligo. Review the FDA label, trial outcomes, timeline, and risks.

Aug 1, 2026 · 5 min · Medically reviewed

Evidence map for hypochlorous acid face spray, separating one older facial-acne solution trial and chronic-wound studies from claims not established for today's consumer mist category.

Patient Ed

Hypochlorous acid face spray: what the evidence shows

Hypochlorous acid face spray is popular, but human evidence mainly comes from wound care. See what HOCl may do, what remains unproven, and safety limits.

Jul 28, 2026 · 5 min · Medically reviewed

AestheticDermatologyNews

Aesthetic

Ablative fractional CO2 laser for acne scars: 2026 evidence

Mechanism, efficacy data, downtime, and the post-inflammatory hyperpigmentation risk that dominates ablative fractional CO2 resurfacing for atrophic acne scars, with a focus on darker and Asian skin.

Jul 2, 2026 · 6 min · Medically reviewed

AestheticDermatologyNews

Aesthetic

Energy-based skin tightening: comparing the options

How microfocused ultrasound, monopolar radiofrequency, and RF microneedling differ for skin tightening, and how clinicians choose the right energy-based option.

Jul 2, 2026 · 4 min · Medically reviewed

MedicalDermatologyNews

Medical

Erythema nodosum: causes, diagnosis, and treatment

Erythema nodosum causes tender red nodules on the shins and often signals an underlying trigger. What causes it, how it is diagnosed, and how it is treated.

Jul 2, 2026 · 5 min · Medically reviewed

MedicalDermatologyNews

Medical

Post-laser hyperpigmentation: prevention and treatment

Why lasers and energy-based devices can trigger post-inflammatory hyperpigmentation, who is most at risk, and what the evidence supports to prevent and treat it.

Jul 2, 2026 · 5 min · Medically reviewed

MedicalDermatologyNews

Medical

Solar lentigines (age spots): causes and treatment

What solar lentigines are, how they differ from other pigmented spots, and what the evidence supports for lasers, IPL, cryotherapy, peels, and topical agents.

Jun 16, 2026 · 3 min · Medically reviewed

MedicalDermatologyNews

Medical

Tranexamic acid for melasma: what the evidence shows

What randomized trials and meta-analyses show about tranexamic acid for melasma, including efficacy by route (oral, topical, injected), safety, and who should avoid it.

Jun 14, 2026 · 3 min · Medically reviewed

MedicalDermatologyNews

Medical

Facial hyperpigmentation: melasma, PIH, or sun spots?

How clinicians tell melasma, post-inflammatory hyperpigmentation, and solar lentigines apart, why it changes treatment and prognosis, and the evidence-based options for each.

Jun 12, 2026 · 4 min · Medically reviewed

MedicalDermatologyNews

Medical

Male pattern hair loss: treatment evidence in 2026

What the evidence supports for male androgenetic alopecia: minoxidil, finasteride and dutasteride, adjunct options, and realistic expectations on results and risks.

Jun 10, 2026 · 3 min · Medically reviewed

MedicalDermatologyNews

Medical

Rosacea 2026: phenotypes, triggers, and treatment

A phenotype-based guide to rosacea: how flushing, persistent redness, papules and pustules, visible vessels, and eye involvement are treated, and why trigger control matters.

Jun 8, 2026 · 4 min · Medically reviewed

MedicalDermatologyNews

Medical

Topical retinoids: tretinoin and gentler alternatives

How topical retinoids work, how prescription tretinoin compares with retinaldehyde, retinol, and adapalene, and how to choose a tolerable option for aging or acne-prone skin.

Jun 7, 2026 · 3 min · Medically reviewed

MedicalDermatologyNews

Medical

Atrophic acne scars: types and treatment in 2026

How clinicians classify atrophic acne scars (ice-pick, boxcar, rolling) and what the evidence supports for subcision, fractional lasers, microneedling RF, and fillers.

Jun 6, 2026 · 4 min · Medically reviewed

MedicalDermatologyNews

Medical

Cutaneous warts: what actually works for verrucae

What the evidence supports for treating common and plantar warts, why salicylic acid and cryotherapy are first-line, and when persistent warts need a different approach.

Jun 5, 2026 · 3 min · Medically reviewed

Agreement categories in the 2025 WFUMB position paper on aesthetic dermatologic ultrasound: 50 percent or less excluded, 50 to 75 percent majority consensus, 75 to 95 percent broad agreement and over 95 percent strong consensus, with acceptance requiring more than 75 percent.

News

WFUMB 2025 position paper: aesthetic ultrasound standardization

The World Federation for Ultrasound in Medicine and Biology (WFUMB) released 24 consensus recommendations standardizing dermatologic ultrasound for aesthetic procedures: what changed and what it means for practice.

May 31, 2026 · 4 min · Medically reviewed

AestheticDermatologyNews

Aesthetic

Do exosome skin treatments work?

Do exosome skin treatments work? Reviews find encouraging short-term signals, but mostly non-randomized studies and unresolved long-term safety gaps remain.

May 30, 2026 · 5 min · Medically reviewed

What the pooled oral minoxidil review covers: 17 studies and 634 patients with several forms of hair loss, most often androgenetic alopecia, so the total is not a women-only sample of female pattern hair loss.

Medical

Female pattern hair loss 2026: topical and oral minoxidil

How topical and low-dose oral minoxidil fit into female pattern hair loss treatment, with evidence on diagnosis, combination therapy, adherence, and adverse effects.

May 30, 2026 · 5 min · Medically reviewed

AestheticDermatologyNews

Aesthetic

Body skin laxity after GLP-1 weight loss: what helps

After rapid weight loss on GLP-1 drugs, loose skin on the abdomen, arms, and thighs is common. What the evidence says about energy-based tightening, biostimulators, timing, and when surgery is the realistic option.

May 30, 2026 · 3 min · Medically reviewed

MedicalDermatologyNews

Medical

GLP-1 hair shedding: is it the drug or the weight loss?

Hair loss reported with semaglutide and tirzepatide: what the evidence shows about telogen effluvium, androgenetic alopecia, diagnosis, and recovery.

May 30, 2026 · 3 min · Medically reviewed

AestheticDermatologyNews

Aesthetic

Radiofrequency microneedling: 2026 evidence review

What 41 studies show about RF microneedling efficacy, how devices differ, and why the FDA's 2025 serious-complication reports limit broad safety claims.

May 30, 2026 · 3 min · Medically reviewed

Recommendation strength in the 2024 American Academy of Dermatology acne guideline: combined oral contraceptives and spironolactone are conditional recommendations, doxycycline is a strong recommendation, and isotretinoin is strongly recommended for severe, scarring, psychosocially burdensome or treatment-resistant acne.

Medical

Adult female acne 2026: hormonal subtype and what works

Why adult-onset acne in women is often hormonally driven, how it differs from adolescent acne, and what the evidence supports for combined oral contraceptives, spironolactone, and topical therapy.

May 29, 2026 · 5 min · Medically reviewed

Three concerns and the treatment the reviews match to each: volume with hyaluronic acid filler (immediate cheek, temple and under-eye volume), dermal quality with polynucleotide injectables (not volume), and laxity with microfocused ultrasound or monopolar radiofrequency.

Aesthetic

Ozempic face (GLP-1) facial volume loss: 2026 review

Why GLP-1 receptor agonists cause facial volume loss, severity predictors, and the published multimodal restoration approaches in 2026.

May 28, 2026 · 8 min · Medically reviewed

Bar chart from a 12-week randomized study in women with Fitzpatrick III to VI skin: among participants with melasma, 36 percent using SPF 50+ sunscreen with an iron-oxide foundation showed superior improvement in skin radiance versus 0 percent using SPF 50+ alone.

Patient Ed

Summer photoprotection 2026: why visible light matters

Why visible light, not just UV, drives melasma and post-inflammatory pigmentation, and what tinted iron oxide sunscreens add to a summer skin care routine in 2026.

May 28, 2026 · 5 min · Medically reviewed

Bar chart from a 2024 prospective study of 30 Asian participants who had three intradermal polynucleotide (PN HPT) sessions: at 6 months, 43 percent rated their skin very much improved and 33 percent much improved.

Aesthetic

Polynucleotide skin boosters (Rejuran): 2026 evidence

What polynucleotide injectables do, what the systematic review data shows, how they compare with HA boosters, adverse events, and patient selection.

May 27, 2026 · 6 min · Medically reviewed

Bar chart from a 2024 multicenter retrospective study of 274 treatment sessions in 167 patients: the most common adverse events were bruising in 6.57 percent of face and 7.69 percent of body treatments and mild pain in 3.07 percent of face treatments; no event needed further intervention.

Aesthetic

Sculptra (poly-L-lactic acid) biostimulator: 2026 evidence

Mechanism of collagen induction, expected timeline, reconstitution evidence, recognized complications, and patient selection for PLLA.

May 26, 2026 · 6 min · Medically reviewed

Findings of a randomized, evaluator-blind split-face trial in 20 people with mild-to-moderate facial laxity followed for 6 months: investigator-rated laxity, patient satisfaction and adverse-event rates did not differ significantly between monopolar radiofrequency and microfocused ultrasound.

Aesthetic

Thermage (monopolar RF) skin tightening: 2026 evidence

Mechanism, timeline, comparator data vs MFU-V, adverse events, and patient selection for monopolar radiofrequency facial tightening.

May 25, 2026 · 5 min · Medically reviewed

Design of a 20-person split-face trial comparing monopolar RF with MFU-V, with assessments on days 30, 90 and 180.

Aesthetic

MFU-V (Ultherapy): Evidence, Safety, and Limits

MFU-V means microfocused ultrasound with visualization in aesthetic medicine. Review skin-tightening results, safety, timelines, and patient selection.

May 24, 2026 · 6 min · Medically reviewed

MedicalDermatologyNews

Medical

Triple combination cream for melasma: 2026 evidence

Evidence for FDA-approved hydroquinone, tretinoin and fluocinolone cream for melasma: efficacy versus monotherapy, adverse effects and adjunctive options.

May 23, 2026 · 5 min · Medically reviewed

Patient EdDermatologyNews

Patient Ed

Energy-based skin tightening: pre-treatment checklist

What patients should ask and clinicians should disclose before MFU-V, radiofrequency or combination skin tightening: a checklist and red flags.

May 22, 2026 · 5 min · Medically reviewed